Reported 3 days ago
Vaxcyte, Inc. (NASDAQ:PCVX) is highlighted as one of the best mid-cap biotech stocks to invest in, given its innovative vaccine development, particularly its VAX-24 pneumococcal conjugate vaccine with significant market potential. Analysts maintain a positive outlook, noting it could outperform existing vaccines due to its advanced technology. With a market cap of $9.26 billion and support from hedge funds, Vaxcyte is well-positioned in an oversaturated biotech sector, although the broader industry faces challenges. Overall, while it shows promise, there are discussions on the greater potential of AI stocks for higher returns.
Source: YAHOO